The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Next-generation sequencing in patients with lymphoid malignancies
Ola Landgren, MD, PhD of Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of his poster session on next generation sequencing in patients with lymphoid malignancies at ASH 2017. A feasibility study has shown that next generation sequencing can be turned around in 7 days and has been set up for MRD assessments as part of the standard of care at the Memorial Sloan Kettering Cancer Center.
Going forward, these assays will be improved for further sensitivy and more importantly, a shorter turn around time.
Recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.
